|
Syncona Ltd on Tuesday noted the continued positive progress in lung cancer trials by its portfolio company.
Syncona is a London-based healthcare company focused on creating, building and scaling a portfolio of global leaders in life science.
Its portfolio, Achilles Therapeutics PLC, is a clinical-stage biopharmaceutical company developing AI-powered precision T-cell therapies to treat solid tumours.
Achilles is currently conducting Phase I/IIa trials, testing the use of clonal neoantigen reactive T cells, or cNeT, from the Chiron study in advanced unresectable or metastatic non-small cell lung cancer.
In its latest update, Achilles said that the safety and tolerability observations of cNeT compare favourably to standard tumour infiltrating lymphocytes, due to less interleukin-2 related toxicity.
It also achieved durable partial response and stable disease in heavily pre-treated NSCLC patients dosed with cNeT monotherapy.
‘We note positively that the company has dosed a further two patients since submitting data to ESMO [Immuno-Oncology Congress 2022], expanding the cohorts across the two trials to 16 patients in total,’ said Syncona’s Chief Executive Officer Martin Murphy.
‘Whilst we are pleased to see the early safety profile of Achilles’ product and a partial durable response, in order for Achilles to be competitive in the space it is operating, it is critical that the company can manufacture at scale and we are looking forward to engaging the company further regarding the optimization of its manufacturing process.’
Syncona shares were trading 1.1% higher at 180.80 pence each in London on Tuesday at midday.
By Holly Beveridge; Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2022 Alliance News Ltd. All Rights Reserved.
|
